Homology Medicines, Inc. (NASDAQ:FIXX) Short Interest Up 14.9% in July

Homology Medicines, Inc. (NASDAQ:FIXXGet Rating) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totalling 1,160,000 shares, an increase of 14.9% from the July 15th total of 1,010,000 shares. Based on an average trading volume of 382,700 shares, the short-interest ratio is presently 3.0 days. Approximately 2.9% of the company’s shares are short sold.

Homology Medicines Stock Up 4.7 %

NASDAQ FIXX opened at $2.89 on Tuesday. The stock has a market capitalization of $165.86 million, a PE ratio of -36.12 and a beta of -0.36. The company has a 50 day moving average price of $2.24 and a two-hundred day moving average price of $2.48. Homology Medicines has a 12-month low of $1.30 and a 12-month high of $8.90.

Homology Medicines (NASDAQ:FIXXGet Rating) last posted its earnings results on Monday, May 16th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.05. The firm had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $1.30 million. Homology Medicines had a negative net margin of 47.29% and a negative return on equity of 49.48%. As a group, equities analysts anticipate that Homology Medicines will post -1.86 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. BTIG Research lowered their price objective on shares of Homology Medicines from $29.00 to $12.00 and set a “buy” rating on the stock in a research report on Tuesday. Credit Suisse Group boosted their price objective on shares of Homology Medicines from $3.10 to $3.21 and gave the company a “neutral” rating in a research report on Tuesday. Chardan Capital lowered their price objective on shares of Homology Medicines to $14.00 and set a “na” rating on the stock in a research report on Tuesday, May 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Homology Medicines in a research report on Monday, May 23rd. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.13.

Institutional Trading of Homology Medicines

A number of institutional investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC acquired a new stake in Homology Medicines in the second quarter valued at approximately $55,000. Millennium Management LLC acquired a new stake in shares of Homology Medicines in the second quarter worth $1,422,000. Virtu Financial LLC acquired a new stake in shares of Homology Medicines in the second quarter worth $34,000. Renaissance Technologies LLC lifted its stake in shares of Homology Medicines by 6.3% in the second quarter. Renaissance Technologies LLC now owns 248,800 shares of the company’s stock worth $490,000 after buying an additional 14,800 shares during the last quarter. Finally, UBS Group AG lifted its stake in shares of Homology Medicines by 677.7% in the second quarter. UBS Group AG now owns 190,122 shares of the company’s stock worth $375,000 after buying an additional 165,674 shares during the last quarter. 58.14% of the stock is currently owned by institutional investors and hedge funds.

Homology Medicines Company Profile

(Get Rating)

Homology Medicines, Inc, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders.

Featured Stories

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.